Mayne Pharma GroupMAYNF 48 Buyback Yield % is 0.00 as of Jul. 02, 2026. GuruFocus rates MAYNF with a GF Score™ of 48/100 and a GF Value™ of $3.87 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 40 Medical Distribution companies, Mayne Pharma Group ranks worse than 2499997.5% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Mayne Pharma Group Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAYNF vs MCK, CAH, COR: Buyback Yield % Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (MAYNF) has a Buyback Yield % of 0.00 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #999999 out of 40 companies in the Medical Distribution industry.
Is Mayne Pharma Group's Buyback Yield % too high?
Mayne Pharma Group's current Buyback Yield % is 0.00. Based on the distribution chart, Mayne Pharma Group ranks #999999 out of 40 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Buyback Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #999999 out of 40 companies for Buyback Yield %. This places Mayne Pharma Group in the lower half of its industry. The industry median Buyback Yield % is 0.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
The median Buyback Yield % among Medical Distribution companies is 0.02, based on 40 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Buyback Yield % is 0.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.87, compared to a current price of $1.65 — trading 57.4% below its estimated fair value. The current Buyback Yield % is 0.00. Mayne Pharma Group's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Buyback Yield % is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $1.65 is trading 57.4% below its estimated GF Value™ of $3.87.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
Buyback Yield %: 0.00
GF Value™: $3.87 vs. price of $1.65 (57.4% below fair value)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
48GF Score
Get the complete analysis for MAYNF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
